Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping
Authors' conclusion
Cohort-wide and cross-disease immunophenotyping elucidate clinically heterogeneous patient subtypes existing within single disease in immune cell type-specific manner.
Study context
- Population
- Japanese patients with 11 autoimmune rheumatic diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), registered in the FLOW study
- Participants
- >1,000 patients11 autoimmune rheumatic diseases (AIRDs)
- Outcome
- Immunophenotypes of 46 peripheral immune cells, clustered
Methodological detailscohort-wide immunophenotyping, 8-colour flow cytometry, multimodal clustering, polygenic risk score analysis
- Cohort-wide immunophenotyping
- 8-colour flow cytometry
- Multimodal clustering
- Polygenic risk score analysis
Main finding
As reported in the abstract
- Close immunological network between MCTD and SLE
- Patient-level clustering split patients with AIRD into several clusters with different immunological features; RA-like or SLE-like clusters exclusively dominant
- In RA, patient clusters defined clinical heterogeneity in disease activity and treatment response, e.g. treatment resistance in RA with SLE-like immunophenotypes
- Polygenic Risk Score (PRS) associated with clinical and immunological characteristics, e.g. dendritic cells implicated in RA-ILD
Observational data: associations, not effects.
Original publication
Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping. Ann Rheum Dis. Published 11 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →